NNBXF Nanobiotix S.A.

NEUTRAL Impact: 3/10 6-K
Horizon weeks Filed Jun 2, 2026 Processed 4d 10h ago SEC 0001171843-26-003863
Notable filing: 6-K

Price Chart

Loading chart...

Executive Summary

Nanobiotix announced its inclusion in the Euronext Tech Leaders Index, a Euronext initiative to increase visibility among international investors for high-growth European tech companies. This is a non-financial, reputational milestone that does not change the company's fundamentals or near-term outlook. The filing comes shortly after two recent capital raises (424B5 filings on May 20 and May 22, 2026) that introduced significant dilution, which remains the dominant factor for the stock.

Actionable Insight

Index inclusion is a modest positive for visibility but does not alter the fundamental picture dominated by recent dilutive capital raises. Monitor for any increased institutional buying driven by index tracking, but the near-term stock price is more likely to be driven by clinical catalysts (NANORAY-312 data) and dilution overhang.

Key Facts

  • Nanobiotix was added to the Euronext Tech Leaders segment and index as of June 2, 2026.
  • The Euronext Tech Leaders initiative was launched in 2022 to increase visibility of leading European tech companies among international investors.
  • No financial terms, revenue figures, or clinical data were disclosed in this filing.
  • This filing follows two recent capital raises: a global offering of ~2.18M shares/pre-funded warrants raising ~€79.12M (May 22) and a preliminary prospectus for up to 75M shares (May 20).

Financial Impact

No financial impact from this filing; index inclusion may modestly increase passive fund flows over time but is not quantifiable from the filing.

Risk Factors

  • Index inclusion does not guarantee increased trading volume or institutional ownership.
  • Recent capital raises (up to 75M shares authorized) create substantial dilution risk that overshadows this non-financial milestone.
  • No change to the company's cash runway or operational outlook was provided.

Market Snapshot

Exchange
OTC
Sector
Pharmaceutical Preparations

Documents Analyzed

This report is based on 5 SEC documents filed with EDGAR.

DocumentAccession Number
6-K Filing (Primary)0001171843-26-003863
Document: f6k_060226.htm0001171843-26-003863
Document: 0001171843-26-003863-index-headers.html0001171843-26-003863
Document: 0001171843-26-003863-index.html0001171843-26-003863
Document: 0001171843-26-003863.txt0001171843-26-003863
10 reports for NNBXF
Performance horizon
Filters
Rows
Reports for NNBXF — sortable, filterable
Type Now
Jun 5, 2026
1d ago
6-K
NEUTRAL ★ 2/10
awaiting T+20
Jun 2, 2026
4d ago
6-K
NEUTRAL ★ 3/10
awaiting T+20
May 26, 2026
11d ago
6-K
BEARISH ★ 5/10
awaiting T+20
May 26, 2026
11d ago
6-K
MIXED ★ 6/10
awaiting T+20
May 22, 2026
15d ago
6-K
BEARISH ★ 6/10
awaiting T+20
May 22, 2026
15d ago
424B5
BEARISH ★ 6/10
awaiting T+20
May 21, 2026
16d ago
6-K
BEARISH ★ 7/10
awaiting T+20
May 21, 2026
16d ago
6-K
BEARISH ★ 6/10
awaiting T+20
May 20, 2026
17d ago
6-K
BEARISH ★ 7/10
awaiting T+20
May 20, 2026
17d ago
424B5
BEARISH ★ 7/10
awaiting T+20
Showing 10 of 10

US Market Status

Market Closed — Opens Mon (14h 51m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access